Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 7/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477298 | 1.00 | GRM5 (0.46) | GRM5NAMPTEGLN1CDK5CDK5R1 | |
| SCHEMBL4484864 | 0.89 | TYK2 (0.40) | NAMPTCDK1 | |
| SCHEMBL4484861 | 0.89 | TYK2 (0.40) | NAMPTCDK1 | |
| SCHEMBL3847376 | 0.88 | CDK5 (0.47) | GRM5NAMPTCDK5CDK5R1CYP2C9 | |
| SCHEMBL4491359 | 0.87 | POLB (0.45) | GRM5NAMPTCDK5CDK5R1CYP2C9 | |
| SCHEMBL4491364 | 0.87 | POLB (0.45) | GRM5NAMPTCDK5CDK5R1CYP2C9 | |
| SCHEMBL4501781 | 0.86 | EPHX2 (0.53) | GRM5NAMPTCDK5CDK5R1CYP2C9 | |
| SCHEMBL4504619 | 0.86 | PIM1 (0.47) | GRM5NAMPTCDK5CDK5R1CYP2C9 | |
| SCHEMBL4504622 | 0.86 | PIM1 (0.47) | GRM5NAMPTCDK5CDK5R1CYP2C9 | |
| SCHEMBL4501778 | 0.86 | EPHX2 (0.53) | GRM5NAMPTCDK5CDK5R1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | GRM5 1539/4885NAMPT 3483/4885EGLN1 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.